Endoscope-assisted Flapless Approach Versus Papillary Preservation Technique in Periodontal Regeneration.
Launched by THE UNIVERSITY OF HONG KONG · May 10, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different surgical techniques for treating periodontal disease, which is a serious gum infection that damages the soft tissue and bone supporting your teeth. The researchers want to compare a newer method called the Endoscope-Assisted Flapless Approach, which uses a small camera and special techniques to regenerate lost tissue without making large cuts in the gums, to the traditional Papilla Preservation Technique, which involves more invasive surgery. Both methods use a biological agent known as Enamel Matrix Derivative (EMD) to help the healing process. The goal is to find out if the flapless method can achieve similar results to the traditional method while being less invasive and more comfortable for patients.
To be eligible for this trial, you should be diagnosed with a more advanced stage of periodontal disease and have specific measurements indicating the severity of your condition. You also need to have good oral hygiene and a stable tooth nearby. However, certain health conditions, like uncontrolled diabetes or smoking, may prevent you from participating. If you join the trial, you will be randomly assigned to one of the two treatment groups, and you can expect to undergo the assigned procedure and have follow-up evaluations to track your healing over the next year. This research aims to improve treatment options for patients with periodontal disease, making recovery easier and more effective.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stage III - Stage IV Periodontitis patients, 3-4 months after completing steps I \& II periodontal therapy.
- • At least 1 tooth presented with 1 site with \>5mm residual PPD and ≥6mm CAL, with ≥3mm intra-osseous defect presented involving predominantly the interdental space of the tooth and presented on paralleling periapical radiographs and/or CBCT.
- • Presence of a periodontally stable tooth with PPD≤3mm immediate adjacent to the intra-bony defect of the investigated tooth
- • Good Oral Hygiene, with Full Mouth Plaque Score ≤25% at baseline and with good plaque control at proposed surgical field.
- Exclusion Criteria:
- • Pre-study period
- • Any systemic condition which prevents following the study protocol;
- • Any systemic condition which may affect healing outcomes of patients, e.g. uncontrolled or poorly controlled diabetes, unstable or life-threatening conditions or those requiring antibiotic prophylaxis;
- • Patients under long-term analgesic medication;
- • Current smokers;
- • Self-reported pregnancy;
- • Systemic antimicrobial therapy within 3 months;
- • Teeth that concurrently present with a buccal and a lingual intrabony defect component;
- • Tooth with hopeless prognosis or questionable prognosis associated with endodontic lesions, or subgingival restorations that preclude clinical measurements, or excessive uncontrolled mobility;
- • Any factors which prohibit regular performance of plaque control around surgical sites;
- • Inadeduate oral hygiene with full mouth plaque score \>25%
- • Furcation involved surfaces
- • During study period -Non-compliance with study protocol
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported